Healome Therapeutics
Develops proprietary eye-drop matrix technology for ocular surface diseases
£2MSeed
Role not disclosedOB
Oshen Bio
Activity from announced rounds
Activity in this selectionxyz-venture-capital-d246227f
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $2.7M 1 disclosed · full round size, not this investor’s share